• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Germany·Healthcare·NXU.DE
Share

Nexus AG Stocks

€ 71.2Last Updated 25.11.2025

Issuer Rating

3/7
Performance

Average

Risk

Considerable

Recommendation

Sell

Market Cap

€ 1.42B

€ 71.2
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Strong margins and returns

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Nexus AG develops and sells software and hardware solutions, and provides IT services, primarily for customers in the health care system worldwide. It operates in two divisions, Healthcare Software and Healthcare Services. The company offers information systems, such as NEXUS/HIS and KIS for somatic hospitals; NEXUS/PSYCHIATRY for psychiatric institutions; NEXUS/REHAB for rehabilitation facilities; ITR, a software for rehabilitation, clinics, and hotels with medical care; NEXUS/ARCHIVE and PEGASOS, an archiving and process management system; NEXUS/QM for quality management; NEXUS/INTEGRATION SERVER, an interface management; NEXUS/CLOUD IT, outsourcing solution; NEXUS/EPS, a software solution to supplement SAP personnel management, as well as process and HR consulting in the SAP environment; ifa systems, an ophthalmology software solution; Sophrona solutions, ophthalmology patients and referral program; and NEXUS/DIS, interdisciplinary diagnostic information system. Its information systems also comprise NEXUS/SWISSLAB, a laboratory information system; NEXUS/LAURIS for order communication in diagnostics; NEXUS/PATHOLOGY and NEXUS/CYTOLOGY for pathology and cytology institutes; dc-Pathos and dc-LabMan for pathology and cytology devices; NEXUS/RADIOLOGY, an information and image system for radiology wards and offices; NEXUs/CHILI, for PACS and teleradiology solutions; NEXUS/ASTRAIA for obstetrics and gynecology; NEXUS/SPECIAL DIAGNOSTICS and Clinic WinData for medical specialist diagnostics and device integration; NEXUS/HOME for senior citizen and nursing homes; NEXUS/OUTPATIENT CARE and Asebis, a homecare solution; NEXUS/PAT, an administration system for hospitals; and osoTEC for billing personal and other services. In addition, the company offers SINAPSI, highsystemNET, CREATIV OM, SEXTANT, Emed, NEXUS/EPD, NEXUS/AEMP, NEXUS/SPM, EuroSDS, RVS Software, NEXUS/VITA and TESIS VITA, and NEXUS/ESKULAP. NEXUS AG is headquartered in Donaueschingen, Germany.

Company Valuation

Greatly overvalued
1/7

Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. Specifically, the stock is 'expensive' on P/E, overvalued on EV/EBITDA,

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Neutral
4/7

The average target price of NXU.DE is 70 and suggests 2% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation to decr

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

13.06.2026 16:01

Highlights in small-caps: record IPO in biotech, Wizz Air success, SpaceX effect

13.06.2026 13:01

An investment idea for all times, IPO of the year and how to keep emotions in check in the stock market

13.06.2026 03:02

Microsoft is considering spinning off Xbox into a separate company - The Information

13.06.2026 01:40

Hope for peace with Iran and SpaceX lifted spirits: stocks rose for second straight day

13.06.2026 01:05

SpaceX shares rose in value by 19% on the first day of trading. Is it worth buying them?

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn
  • X (Twitter)
  • LinkedIn
Oninvest© 2026